NYSE:RMED - RA Medical Systems Stock Price, News, & Analysis

$3.48
+0.13 (+3.88 %)
(As of 06/20/2019 03:02 PM ET)
Today's Range
$3.39
Now: $3.48
$3.55
50-Day Range
$2.92
MA: $3.79
$4.83
52-Week Range
$2.90
Now: $3.48
$22.00
Volume2,214 shs
Average Volume46,420 shs
Market Capitalization$45.00 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Ra Medical Systems, Inc., a commercial-stage medical device company, develops, manufactures, and markets excimer lasers for use in the treatment of vascular and dermatological diseases. The company offers DABRA (destruction of arteriosclerotic blockages by laser radiation ablation), a minimally-invasive excimer laser and disposable catheter system that is used by physicians in the endovascular treatment of vascular blockages resulting from lower extremity vascular disease. It also provides Pharos, an excimer laser device that emits highly concentrated ultraviolet light used in the treatment of dermatological skin disorders. The company sells its products primarily through its direct sales force in the United States. Ra Medical Systems, Inc. was founded in 2002 and is headquartered in Carlsbad, California.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone760-804-1648

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$6.26 million
Book Value$5.26 per share

Profitability

Miscellaneous

Employees95
Market Cap$45.00 million
Next Earnings Date8/12/2019 (Estimated)
OptionableNot Optionable

Receive RMED News and Ratings via Email

Sign-up to receive the latest news and ratings for RMED and its competitors with MarketBeat's FREE daily newsletter.

RA Medical Systems (NYSE:RMED) Frequently Asked Questions

What is RA Medical Systems' stock symbol?

RA Medical Systems trades on the New York Stock Exchange (NYSE) under the ticker symbol "RMED."

How were RA Medical Systems' earnings last quarter?

RA Medical Systems Inc (NYSE:RMED) released its quarterly earnings results on Monday, May, 13th. The company reported ($1.16) EPS for the quarter, missing analysts' consensus estimates of ($0.38) by $0.78. The business earned $1.75 million during the quarter, compared to the consensus estimate of $1.22 million. View RA Medical Systems' Earnings History.

When is RA Medical Systems' next earnings date?

RA Medical Systems is scheduled to release their next quarterly earnings announcement on Monday, August 12th 2019. View Earnings Estimates for RA Medical Systems.

What price target have analysts set for RMED?

4 equities research analysts have issued 12-month price targets for RA Medical Systems' stock. Their forecasts range from $10.00 to $23.00. On average, they expect RA Medical Systems' share price to reach $14.00 in the next twelve months. This suggests a possible upside of 302.3% from the stock's current price. View Analyst Price Targets for RA Medical Systems.

What is the consensus analysts' recommendation for RA Medical Systems?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for RA Medical Systems in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for RA Medical Systems.

What are Wall Street analysts saying about RA Medical Systems stock?

Here are some recent quotes from research analysts about RA Medical Systems stock:
  • 1. According to Zacks Investment Research, "Ra Medical Systems, Inc. is a commercial-stage medical device company. It develops, manufactures, and markets excimer lasers for use in the treatment of vascular and dermatological diseases. The company's product pipeline consists of DABRA which is a minimally-invasive excimer laser and disposable catheter system used by physicians as a tool in the endovascular treatment of vascular blockages resulting from lower extremity vascular disease, a form of peripheral artery disease, or above- and below-the-knee. Pharos Excimer Laser is a powerful 308 nm ultraviolet-B excimer laser used by physicians as a tool to treat chronic skin diseases, including psoriasis, vitiligo, atopic dermatitis and leukoderma. Ra Medical Systems, Inc. is based in Carlsbad, California. " (6/20/2019)
  • 2. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating and $11 PT. RMED hosted a call with its new Chief Commercial Officer (CCO), Thomas Fogarty, and its covering analysts this afternoon to discuss the company’s new commercial strategy. We came away from the call with a better understanding of Mr. Fogarty’s strategy and the changes being made to align the sales and marketing organization with the commercialization strategy. On the call, Mr. Fogarty articulated his vision for the company, his successes in prior commercial organization turnarounds and his motivation for taking the position with RMED." (3/26/2019)

Has RA Medical Systems been receiving favorable news coverage?

Media headlines about RMED stock have been trending somewhat negative on Thursday, according to InfoTrie. The research firm rates the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. RA Medical Systems earned a coverage optimism score of -1.0 on InfoTrie's scale. They also gave news stories about the company a news buzz of 9.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the next few days. View News Stories for RA Medical Systems.

Are investors shorting RA Medical Systems?

RA Medical Systems saw a increase in short interest in May. As of May 31st, there was short interest totalling 466,900 shares, an increase of 23.5% from the April 30th total of 378,200 shares. Based on an average trading volume of 122,300 shares, the short-interest ratio is presently 3.8 days. Currently, 6.2% of the company's shares are short sold. View RA Medical Systems' Current Options Chain.

Who are some of RA Medical Systems' key competitors?

What other stocks do shareholders of RA Medical Systems own?

Based on aggregate information from My MarketBeat watchlists, some companies that other RA Medical Systems investors own include Corbus Pharmaceuticals (CRBP), Globalstar (GSAT), Pareteum (TEUM), Pareteum (TEUM), Adobe (ADBE), Opko Health (OPK), AK Steel (AKS), Chevron (CVX), CarMax (KMX) and Abeona Therapeutics (ABEO).

Who are RA Medical Systems' key executives?

RA Medical Systems' management team includes the folowing people:
  • Mr. Dean Irwin, CEO, Chief Technology Officer & Chairman of Director (Age 56)
  • Mr. Jeffrey Jay Kraws, Pres (Age 55)
  • Ms. Melissa Burstein, Exec. VP & Director (Age 43)
  • Mr. Richard Heymann, Director of Corp. Strategy & Bus. Devel. (Age 64)
  • Mr. Andrew C. Jackson, Chief Financial Officer (Age 50)

When did RA Medical Systems IPO?

(RMED) raised $50 million in an IPO on Thursday, September 27th 2018. The company issued 3,300,000 shares at $14.00-$16.00 per share. Piper Jaffray and Cantor served as the underwriters for the IPO and SunTrust Robinson Humphrey, Nomura and Maxim Group were co-managers.

Who are RA Medical Systems' major shareholders?

RA Medical Systems' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Wasatch Advisors Inc. (1.87%), Alethea Capital Management LLC (1.61%), Janus Henderson Group PLC (1.05%) and Meitav Dash Investments Ltd. (0.92%). Company insiders that own RA Medical Systems stock include Andrew C Jackson, Dean Irwin and Jeffrey J Kraws. View Institutional Ownership Trends for RA Medical Systems.

Which major investors are selling RA Medical Systems stock?

RMED stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC. Company insiders that have sold RA Medical Systems company stock in the last year include Andrew C Jackson, Dean Irwin and Jeffrey J Kraws. View Insider Buying and Selling for RA Medical Systems.

Which major investors are buying RA Medical Systems stock?

RMED stock was acquired by a variety of institutional investors in the last quarter, including Alethea Capital Management LLC, Wasatch Advisors Inc. and Meitav Dash Investments Ltd.. View Insider Buying and Selling for RA Medical Systems.

How do I buy shares of RA Medical Systems?

Shares of RMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is RA Medical Systems' stock price today?

One share of RMED stock can currently be purchased for approximately $3.48.

How big of a company is RA Medical Systems?

RA Medical Systems has a market capitalization of $45.00 million and generates $6.26 million in revenue each year. The company earns $-30,830,000.00 in net income (profit) each year or ($3.34) on an earnings per share basis. RA Medical Systems employs 95 workers across the globe.View Additional Information About RA Medical Systems.

What is RA Medical Systems' official website?

The official website for RA Medical Systems is http://www.ramed.com/.

How can I contact RA Medical Systems?

RA Medical Systems' mailing address is 2070 Las Palmas Drive, Carlsbad CA, 92011. The company can be reached via phone at 760-804-1648 or via email at [email protected]


MarketBeat Community Rating for RA Medical Systems (NYSE RMED)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  40 (Vote Outperform)
Underperform Votes:  58 (Vote Underperform)
Total Votes:  98
MarketBeat's community ratings are surveys of what our community members think about RA Medical Systems and other stocks. Vote "Outperform" if you believe RMED will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RMED will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/20/2019 by MarketBeat.com Staff

Featured Article: Trade War

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel